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Introduction
Photodynamic therapy is used to treat superficial malignant lesions affecting cutaneous and mucosal surfaces. 1, 2 Early studies used a mixture of porphyrins called photofrin as an exogenous photosensitiser but troublesome skin photosensitisation persisting for many weeks after treatment has motivated a search for better agents. Recent studies have focused on ␦-aminolaevulinic acid (ALA) which is converted to protoporphyrin IX (PpIX) by the enzymes of the heme biosynthetic pathway. PpIX is an efficient photosensitiser which induces mitochondrial permeability transition pore opening and apoptosis. 3, 4 ALA is produced from succinyl CoA and glycine by the enzyme ALA synthase (ALA-S). Since ALA-S is the rate limiting step in PpIX synthesis, exogenous ALA is efficiently converted to PpIX. 5 ALA-S production is tightly regulated in the cell, presumably to avoid the toxic accumulation of PpIX and related porphyrins. There are two forms of ALA-S, an erythroid form and a constitutive or hepatic form. Translation of the erythroid form is coordinated with the availability of iron by iron response elements (IREs) in the 5Ј-untranslated region in the mRNA. 6 Both forms of the enzyme contain sequences called heme regulatory motifs (HRMs) which bind heme and prevent mitochondrial import of the ALA-S pro-enzyme. 7 Mutation of the HRMs permits import and processing of the pro-enzyme to the mature form irrespective of the cytoplasmic heme concentration.
There is no specific mechanism targeting PpIX production to tumour cells following ALA treatment. Thus, as with previous photosensitisers, there is a risk of damage to normal tissue during photodynamic therapy and patients can suffer serious burns from accidental exposure to sunlight after finishing treatment. To address this problem we have developed a gene therapy approach which will make it possible to limit photosensitisation to cells in a defined area or of a defined type. To show that virus-directed photosensitisation is feasible we have constructed an adenovirus constitutively expressing a mutant form of human erythroid ALA-S lacking the iron response elements and heme regulatory motifs. To produce the virus we used a new yeast vector system for manipulation of the adenovirus genome. We show that the ALA-S virus induces PpIX accumulation and light-induced apoptosis of cells in culture. Similar to HSV thymidine kinase, mutant ALA-S expression is a general mechanism for sensitisation to a therapeutic agent which can easily be adapted to whatever means of gene delivery is most effective.
Results

Construction of an ALA-S mutant adenovirus
To circumvent heme-dependent regulation of mitochondrial import of human erythroid ALA-S the conserved cysteines in the three HRMs were changed to serine by site-directed mutagenesis (Figure 1 ). The mutant ALA-S cDNA was then cloned into an adenoviral vector ( Figure 2 ). Normal transcriptional and translational control of ALA-S expression are circumvented in this vector because the endogenous promoter is replaced by the cytomegalovirus immediate-early promoter and the truncated 5Ј-untranslated region of the cloned mRNA lacks the iron response elements.
The two-step gene replacement procedure used to construct the ALA-S virus is a modified form of the technique developed by Ketner et al. 8 Unlike the Ketner system, the vector contains sequences for maintenance as a low copy number plasmid in bacteria, and to simplify the production of E1-replacement viruses a counterselectable marker is present at the CMV cloning site (see Figure 2 for details).
The ALA-S mutant is correctly targeted to mitochondria To determine whether ALA-S protein was expressed by the virus, H1299 lung carcinoma cells were infected with the virus and immunoblots were probed with two different anti-ALA-S antibodies ( Figure 3 ). Both antibodies detected a protein of the correct molecular weight (59 kDa). ALA-S is synthesised as a 65 kDa precursor which is cleaved to yield the mature protein after import into mitochondria (the cleavage site is marked by an arrowhead in Figure 1 ). The band marked by an asterisk (Figure 3 , lane 5), which was only seen at high multiplicity of infection, corresponds in size to the unprocessed form. The fact that most of the immunoreactive material has a molecular weight of 59 kDa suggests that it has been correctly imported into mitochondria. To determine its location more exactly, infected cells were stained with anti-ALA-S antibody and examined by confocal microscopy ( Figure 4b ). No staining was seen in uninfected cells or Ad-CMV-lacZ adenovirus-infected controls, showing that the staining was specific to the ALA-S virus (data not shown). The lipophilic cationic dye choromethyl-X-rosamine was used as a marker for mitochondria (Figure 4a) . Superimposition of the confocal micrographs (Figure 4c) showed that the punctate ALA-S staining colocalised with mitochondria. Thus the ALA-S virus expresses a mutant protein that is correctly imported into mitochondria and processed.
PpIX induction after ALA-S virus infection
Since ALA-S is the rate-limiting enzyme in the heme pathway, overexpression of functional ALA-S in mitochondria should lead to an increase in protoporphyrin IX (PpIX) and heme synthesis. PpIX production can be detected by its characteristic fluorescence after excitation at 409 nm. To determine whether the ALA-S virus encodes a functional enzyme we examined PpIX fluorescence of infected H1299 cells. As a negative control we used untreated cells and Ad-CMV-lacZ virus-infected cells. As a positive control we treated cells with ALA, which is known to increase PpIX production. As an additional test of specificity, we examined the effect of iron chelation using desferrioxamine. PpIX is normally converted to heme by ferrochelatase-dependent incorporation of iron. Iron chelation blocks this step, resulting in a specific increase in PpIX levels. Figure 5a shows that the control virus had no effect on PpIX fluorescence, even after treatment with desferrioxamine. ALA treatment produced a large increase in fluorescence, particularly after iron chel- 
Figure 3 ALA-S expression after ALA-S virus infection. Lanes 1 and 2: immunoblot with antibody against a peptide from exon 4 of ALA-S (lane 1, uninfected control; lane 2, cells infected at an MOI of 100). Lanes 3-6: immunoblot with antibody against full length ALA-S (lanes 3-5, cells infected at an MOI of 1-100; lane 6, uninfected control). Cell extracts were prepared 24 h after infection of Saos-2 cells.
ation. ALA-S virus produced an even greater increase in PpIX level in the absence of desferrioxamine, with a further doubling in level after iron chelation. To confirm the specificity of the response further we examined the fluorescence emission spectrum of the infected cells ( Figure 5b ). This showed that both ALA and ALA-S treatment induce an emission peak at the same wavelength. The wavelength of the PpIX peak depends on pH, and corresponds to that induced by ALA and ALA-S under the acid conditions used to make the cell extracts ( Figure 5b , top panel). In summary, fluorimetry suggests that the ALA-S virus encodes a functional enzyme that induces PpIX accumulation to levels comparable with those achieved by treatment of cells with large doses of ALA.
Phototoxicity induced by ALA-S virus
PpIX induces mitochondrial permeability transition and apoptotic death. 4 This is potentiated by light, explaining the use of ALA for phototherapy. To determine whether the ALA-S virus induced apoptosis, we illuminated H1299 cells and performed flow cytometry 72 h after a b c
Figure 4 Mitochondrial localisation of ALA-S after ALA-S virus infection. (a) Mitochondrial staining with chloromethyl-X-rosamine. (b) ALA-S staining with antibody against full-length protein. (c) Superimposition of the images in (a) and (b). Saos-2 cells were stained 24 h after infection at an MOI of 10. The image shows a single cell whose nuclear diameter is 25 m in the long axis.
infection with lacZ and ALA-S viruses ( Figure 6a ). Control virus gave 0.5% hypodiploid cells, a value unaffected by iron chelation. In contrast, the hypodiploid population after ALA-S infection was 16%, rising to 29% after desferrioxamine treatment. To confirm that the mode of death was apoptotic, cells were infected as above and tested for DNA cleavage by TUNEL assay and caspase-mediated keratin cleavage with the M30 antibody. Both tests were strongly positive (data not shown). Thus the ALA-S virus induces apoptosis, and the response to iron chelation is consistent with death being due to a mechanism dependent on PpIX production, however, this does not necessarily mean the virus photosensitises because the cells were continuously exposed to light during this experiment.
To determine whether the ALA-S virus can photosensitise cells in culture, we performed flow cytometry of infected cells grown in the presence and absence of light (Figure 6b ). To illuminate cultured cells continuously a fibreoptic light source was placed inside the incubator. Control cultures were placed in black plastic bags and manipulated in a darkened room. All cultures were treated with desferrioxamine. The hypodiploid population 2 and 3 days after infection in the absence of light was 1% and 4% in H1299, 5% and 11% in Saos-2. In the presence of light it was 6% and 24% in H1299, 22% and 29% in Saos-2 (each figure is the mean of two experiments). Thus the ALA-S virus confers photosensitivity on cells in culture.
Discussion
We have developed a new approach to photodynamic therapy based on adenoviral transduction of the rate-limiting enzyme in heme synthesis. Unlike conventional photodynamic therapy, a viral approach makes it possible to restrict photosensitivity using biological rather than purely physical or chemical means. The need for this type of restriction is illustrated by the fact that patients treated with photosensitising chemicals occasionally develop serious burns following inadvertent exposure to sunlight.
The existing virus is similar to many adenoviruses now used for gene therapy which place expression of a foreign gene under the control of the CMV promoter. While this has allowed us to demonstrate unequivocally that ALA-S induces photosensitivity, tumour targeting will require the development of new viruses with tumour-specific promoters. The YAC/BAC system we have developed makes construction of these vectors a straightforward task. Tumour targeting can be achieved with E2F, Gli, Tcf and RBP-responsive promoters. [9] [10] [11] [12] The activity of these promoters is increased in tumours cells with defects in the Rb, patched, wnt and notch pathways. Unlike tissuespecific promoters, activation of these promoters is directly linked to the causal oncogenic mutations in tumours. Rb pathway defects occur in many tumour types, including head and neck cancers, 13 wnt defects are a hallmark of colon cancer, [14] [15] patched and smoothened defects are common in basal cell cancer, [16] [17] and notch defects are found in some leukaemias.
18 P53-responsive promoters could also be used in cases retaining wild-type p53, for example, cells with mutation of p53 target genes. 19 Photosensitisation by our ALA-S mutant is not restricted to adenoviral vectors. Similar to HSV thymidine kinase, it is a general mechanism for sensitisation to therapeutic agents which can easily be adapted to whatever means of gene delivery is most efficient. The choice of vector or vehicle depends on the tissue to be targeted. Photodynamic therapy itself is limited to treatment of superficial lesions in skin and mucosae because even the most intense light penetrates only a short distance through tissue. One application which would lend itself to the viral approach is topical treatment of preneoplastic lesions in bronchial epithelium, because the abnormal cell layer is present on the surface of the epithelium and protocols already exist for photodynamic therapy of bronchus. 20 ALA-S converts glycine and succinyl-CoA to ALA. This is the rate-limiting step in heme synthesis and is subject to multiple layers of regulation to prevent the formation of photoxins in normal cells. Although it is conceivable that overexpression of the wild-type enzyme would photosensitise, we consider this extremely unlikely because of post-transcriptional regulation of ALA-S expression. We chose instead to test directly a virus encoding a mutant form of the ALA-S cDNA lack- 
Figure 6 Photosensitisation by ALA-S virus. (a) Flow cytometry 3 days after infection of H1299 cells with ALA-S virus and lacZ virus at an MOI of 10. Cells were continuously exposed to light. The gate used to calculate the percentage of hypodiploid (apoptotic) cells is indicated. Desferrioxamine was used to prevent conversion of PpIX to heme. (b) Flow cytometry 3 days after infection of H1299 and 2 days after infection of Saos-2 cells with ALA-S virus at an MOI of 10. Cells were either continuously exposed to light (right panels) or placed in black plastic bags to exclude light (left panels). Desferrioxamine was added to all cultures.
ing the iron response elements and the heme regulatory motifs. 6, 7 The former impose iron-dependent inhibition of ALA-S mRNA translation, which prevents synthesis of PpIX when there is no iron available to convert it into heme. The latter impose end-product inhibition of mitochondrial import by heme, which avoids production of heme in excess of that needed for incorporation into proteins such as haemoglobin, cytochrome c, catalase and peroxidase. The primary mechanism of photosensitisation is due to accumulation of PpIX, which binds to the peripheral benzodiazepine receptor and triggers the mitochondrial permeability transition. 4 Increased heme production does not photosensitise but could influence apoptosis indirectly, given the key regulatory role cytochrome c plays in activating caspase 9.
21 Intriguingly, the cell limits the availability of heme following oxidative stress by strongly inducing heme oxygenase, suggesting that heme itself may exacerbate oxidative damage. 22 We have developed a new set of vectors for constructing recombinant adenoviruses. Our approach is an improved version of the YAC system developed by Ketner et al. 8 The key difference is that we include a bacterial artificial chromosome (BAC) replication origin in the vector. Production of large amounts of DNA in bacteria permits verification of the structure of the construct by sequencing before transfection of mammalian cells and greatly improves the yield of virus after transfection. For the production of simple E1 replacement viruses we have made a counterselectable vector which simplifies the yeast manipulations and results in virtually 100% of recombinants containing the desired changes.
Two other groups have recently described bacterial homologous recombination systems for manipulating the adenovirus genome. 23, 24 The Vogelstein approach is essentially limited to the production of E1 replacement vectors. 23 The Transgene approach can be used to introduce mutations elsewhere in the viral genome, but is dependent on the availability of unique restriction sites at or near the target sequence in the viral genome and requires relatively large vectors to achieve an acceptably low background. 24 Two-step gene replacement in yeast has the merit that it requires only short regions of overlap (a few hundred base pairs) and gives a low background of non-homologous recombinants because the efficiency of homologous recombination is many orders of magnitude higher in yeast than bacteria. The homologous regions should contain one unique restriction site to permit linearisation of the vector, but this is rarely a problem because of the small size of the vectors employed. Thus the main advantage of our system is the ability to introduce subtle mutations at any site in the adenovirus genome without the need to manipulate more than a few hundred base pairs of adenoviral DNA in vitro, coupled with the ability to verify the presence of the desired mutations before converting DNA into virus. This will be particularly useful for directed mutagenesis to improve the tolerance of adenoviral gene therapy vectors by the recipient host cell.
Materials and methods
Plasmid construction IMAGE clone 201112 (pJG19) containing full-length human erythroid ALA-S cDNA in pT3T7D was supplied by Resgen (Huntsville, AL, USA). The heme regulatory motifs (HRMs) were mutagenised in two rounds of inverse PCR. 25 HRMI and 2 were mutated by PCR from pJG19 with oligonucleotides G49 (5Ј-AGG AGG CTT GTG GGG CCC CTG GCA AGC ACT GGG CTG CAC TGT AGC-3Ј, mutant residues are underlined) and G50 (5Ј-AGG CAA GGT GGT TAA GAC TCA CCA GTT CCT GTT TGG TAT TGG ACG CTC TCC CAT CCT G-3Ј), followed by self-ligation to give pJG20. HRM3 was mutated by PCR from pJG20 using G51 (5Ј-AGT GGC CCT TCG CCC AAG ATG-3Ј) and G52 (5Ј-CTC CCT TCA TGC TGT CGG AAC-3Ј) followed by self-ligation to give pJG21. The PCR was performed with a Taq/Pwo polymerase mixture according to the manufacturer's instructions (Expand High Fidelity PCR System; Boehringer, Mannheim, Germany) using 10 cycles of 94°C/15 s 55°C/30 s 65°C/3 min, then 15 cycles with 20 s increments of the elongation phase to amplify the entire 4.8 kb plasmid. An XmnI fragment containing only the desired mutations was backcloned into pJG19 to give pJG22.
To construct the ALA-S integrating vector, an XbaI/EagI pCMV-␤globin intron-p53-␤globin poly A cassette from pC53-SN3 26 was first cloned into the HindIII/EagI sites of pRS406 27 to give pJG23. An EcoRIHindIII ALA-S fragment from pJG22 was then inserted into the EcoRI-EagI sites in pJG23 to give pJG33, and a BamHI-SacII ␤globin polyA fragment from pJG23 was cloned into the PacI-SacII sites of pJG33 to give pJG24, the CMV-␤globin intron-ALA-S-␤globin poly A gene transfer vector.
The YAC/BAC vector is based on pNKBAC39. 28 To allow gap repair cloning of adenoviral DNA, left and right ITR-containing fragments were PCR amplified from wild-type adenovirus 5 (ATCC VR-5) using oligonucleotides G74 (Ad5 left arm; 5Ј-GGG CGA GTC TCC ACG TAA ACG-3Ј), G75 (Ad5 right arm; 5Ј-GGG CAC CAG CTC AAT CAG TCA-3Ј) and G76 (Ad5 ITR plus EcoRI, HindIII and PacI sites; 5Ј-CGG AAT TCA AGC TTA ATT AAC ATC ATC AAT AAT ATA CC-3Ј). The PCR was performed with Pfu polymerase (Stratagene, La Jolla, CA, USA) using 20 cycles of 94°C/15 s 50°C/30 s 78°C/60 s. The G74-G76 (390 bp) and G75-G76 (356 bp) PCR products were digested with EcoRI and cloned into the EcoRI/SmaI sites in the pUC19 polylinker to give pMB1 and 2 which were sequenced to verify the absence of PCR mutations. EcoRI/SalI ITR fragments from pMB1 and 2 were cloned into the BamHI/Bsu36I sites in pNKBAC39 to give pMB10. An SmaI/HindIII ARS fragment from pH4ARS 29 was cloned into the SacI site of pMB10 to give pMB19. This vector has a unique SalI site separating the two ITR fragments and PacI sites flanking the ITR fragments as well as CEN (centromere) 30 and ARS (autonomously replicating sequence) 30 elements for propagation as a low copy plasmid in yeast, HIS3 (imidazole glycerol-phosphate dehydratase) 30 for selection in yeast and an FЈ origin and chloramphenicol resistance gene for propagation as a low copy plasmid in bacteria.
An E1/E3-deleted adenovirus (vMB10) containing a pCMV-␤globin intron-␤globin poly A cassette in the E1 region (equivalent to empty vector) was derived from Ad-CMV-lacZ (Verca and Rusconi, unpublished) by twostep gene replacement in a YAC.
8 vMB10 viral genomic DNA was cloned in yeast strain YPH857 by homologous recombination with pMB19 digested with SalI, to give strain yMB3. The Ad-CMV plasmid it contains is called pMB23. To allow selective excision from YAC/BACs in yeast, the CYH2 gene was inserted between the ␤globin intron and ␤globin polyA site in pMB23. To do this a BamHI fragment from p680 8 containing the CYH2 gene was first cloned at the BamHI site between the ␤globin intron and ␤globin polyA sequences in pJG23 to give pJG32. yMB3 was then transformed with pJG32 cut with SnaBI, which linearises the plasmid within the CMV promoter, followed by two-step gene replacement selecting for and against URA3, to give strain yJG54. The CYH2 YAC/BAC it contains is called pJG54.
The HRM-mutant ALA-S gene was inserted into pJG54 by transformation of yJG54 with pJG24 cut with SnaBI, followed by two-step gene replacement selecting for URA3 and against CYH2, to give strain yJG56. The YAC/BAC it contains, pJG56, was transferred to E. coli strain DH10B and its structure was checked by restriction mapping and DNA sequencing to confirm the presence of the HRM mutations.
YAC/BAC manipulation and virus production Yeast was cultured using standard techniques and transformed by the lithium acetate procedure. 30 The genotype of YPH857 is Mat␣ ura3-52 lys2-801 ade2-101 his3⌬200 trpl ⌬63 leu2⌬1 cyh2 R kar1 ⌬15. The cyh2 R allele in YPH857 confers recessive resistance to cycloheximide. The wildtype CYH2 gene, which encodes the L29 ribosomal protein, confers dominant sensitivity to cycloheximide. 30 Hence, YPH857 cells containing the wild-type plasmidencoded CYH2 gene are sensitive to cycloheximide but can become resistant by losing the plasmid-encoded allele. For two-step gene replacement in yJG54, the strain was transformed with linearised integration vector (pJG24) and plated on ura-medium (SC -ura) to select for integration. Single colonies were picked and grown overnight in rich medium (YPDA) to allow excision to occur. An aliquot of the YPDA culture was plated on medium containing cycloheximide and lacking histidine (SC −his +cyh) to select for recombinants lacking CYH2. Single colonies were grown overnight in 10 ml cultures of SC −his +cyh, and genomic DNA was ethanol precipitated from spheroplasts lysed with SDS. 30 (To avoid rearrangement of the BAC it is important to use a technique for yeast DNA preparation which does not shear the DNA.) Genomic DNA was electroporated into DH10B. The presence of CYH2 means that restreaking of yeast colonies is not required and superfluous copies of the parental YAC/BAC are automatically lost.
YAC/BAC DNA was extracted from a 11 culture of DH10B by alkaline lysis. 31 After isopropanol precipitation the denaturation step was repeated to reduce contamination with chromosomal DNA. YAC/BAC DNA was further purified by ion exchange chromatography (G100 genomic tip; Qiagen, Hilden, Germany), digested with PacI to liberate the adenoviral insert and transfected into 293T cells by the CaPO 4 technique. 31 To avoid overgrowth the cells were passaged the day after transfection. Foci appeared 1 week after transfection. Virus was plaque purified on HER911 cells. Viral stocks were purified by caesium chloride ultracentrifugation, dialysed against 10 mm Tris pH 8, 1 mm MgCl 2 , 10% glycerol and stored at −70°C. To improve yield the HER911 culture flasks were placed in black plastic bags and cells were manipulated in a darkened room. Viral titre (p.f.u.) was measured on HER911 cells. To confirm that the virus had the desired structure, genomic viral DNA was extracted from an aliquot of the final virus prep by proteinase K digestion, restriction mapped and sequenced in the region of the HRM mutations. The control Ad-CMV-lacZ virus was provided by Dr S Rusconi (Verca and Rusconi, unpublished).
Cell lines and culture conditions HER911 32 and 293T 33 are helper cell lines expressing adenovirus early gene products which permit growth of E1-deleted viruses. H1299 non-small cell lung carcinoma cells and Saos-2 osteosarcoma cells were cultured in phenol red-free DMEM with 10% fetal calf serum. Cells were seeded 24 h before drug or virus administration and were 50-70% confluent at the time of treatment. Virus was added to the medium and left on the cells for 8 h, then the medium was replaced with fresh DMEM 10% FCS. ALA (A7793; Sigma, Buchs, Switzerland) was resuspended in culture medium. For ALA treatment, cells were washed in serum-free medium and incubated for 6 h in serum-free medium containing 5 mm ALA, then the medium was replaced with fresh DMEM 10% FCS. Desferrioxamine (Novartis, Basle, Switzerland) was resuspended in distilled water and added at a final concentration of 50 m 12 h before harvesting the cells.
Immunoblotting H1299 cells were infected with Ad-CMV-ALAS at the stated multiplicity and harvested after 24 h. Immunoblotting was performed as described. 34 Anti-ALA-S antibodies were provided by Dr TM Cox. 35 Anti-exon 4 antibody was used at 1/1000 and anti-full-length ALA-S antibody was used at 1/5000. Detection was with HRPconjugated goat anti-rabbit IgG (Jackson Labs, West Grove, Philadelphia, PA, USA) and chemiluminescence (Amersham, Little Chalfont, UK).
Measurement of cellular PpIX content
Forty-eight hours after infection or ALA treatment, H1299 cells were washed in PBS and harvested in acidified methanol (3 mm HCl in methanol). After 15 min incubation, cell debris was removed by centrifugation. A CytoFluor 400 multi-well reader (PerSeptive Biosystems, Perkin-Elmer, Norwalk, CT, USA) was used to measure 645 nm fluorescence after excitation at 409 nm. A PerkinElmer LS 50 spectrofluorimeter (Perkin-Elmer) was used to measure emission spectra from 450 to 750 nm after excitation at 409 nm. The PpIX standard (Sigma) was dissolved in acidified methanol.
Flow cytometry, TUNEL and M30 staining Floating and adherent cells were fixed in 80% ethanol overnight, rinsed in PBS 1% BSA, resuspended in 1 ml propidium solution (10 mm Tris HCl, pH 7.5, 5 mm MgCl 2 , 50 g/ml propidium iodide, 10 g/ml RNase A) and incubated for 30 min at 37°C. Stained cells were analysed in a FACScan (Becton Dickinson, Franklin Lakes, NJ, USA). Half the output of a 90 W cold light source (100 CLS; Leica, Wetzlar, Germany) was used to illuminate the cells by means of a fibre-optic light guide ending inside the incubator roughly 20 cm from the culture dishes. TUNEL and M30 staining were performed according to the manufacturer's instructions (No. 2140322 and No. 1684817; Boehringer). In the TUNEL assay fluoresceinconjugated dUTP is attached to DNA strand breaks by terminal transferase. The epitope recognised by the M30 monoclonal antibody is only present in caspase-cleaved keratin 18. M30 was detected with FITC-coupled secondary antibody (Jackson Labs).
Immunostaining
Thirty minutes before harvesting the cells, 100 l of chloromethyl-X-rosamine (M7512; Molecular Probes, Eugene, OR, USA) was added to the culture medium. Cells were then rinsed with PBS, fixed for 20 min with 4% paraformaldehyde, permeabilised with 50% acetone in methanol and dried. Anti-full-length ALA-S antibody diluted 1/50 in DMEM was applied for 3 h, followed by FITC-coupled secondary antibody (Jackson Labs) for 2 h. Fluorescence was analysed with a confocal microscope (Zeiss, Jena, Germany) using rhodamine and fluorescein filters, a CCD camera (Photometrics, Tucson, AZ, USA) and IP Lab Spectrum software (IP Lab, Vienna, VA, USA).
